Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115231 · ClinicalTrials.gov registry record
Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
A clinical trial of Macular Degeneration, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 223
- Enrollment target
- 2
- Study locations
NCT01115231 is a study of Macular Degeneration that has completed, run by VA Office of Research and Development. The registered enrollment target is 223 participants, above the 171-participant average among 26 other Macular Degeneration trials with a reported enrollment target (30% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01115231, a study of Macular Degeneration, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 223 participants
- Enrollment target
- 2
- Study locations
Study Summary
Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system. Smoking is the only environmental factor known to increase the risk of Age-related Macular Degeneration (AMD). Using serum samples of Age-related Macular Degeneration (AMD) patients and controls the investigators will test the hypothesis that smoking increases Age-related Macular Degeneration (AMD) by increasing complement activation; and that this is positively correlated with known disease variations in the complement factor H (CFH) gene.
Conditions Studied
Study Locations (2)
South Carolina
- Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2010-10 |
| Est. Completion | 2016-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01115231
The ClinicalTrials.gov registry entry for NCT01115231 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 171-participant average among 26 other Macular Degeneration trials with a reported enrollment target (30% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 0 interventions.
NCT01115231 reports 2 study locations spanning 2 distinct geographic areas - top geographies include South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01115231 about?
NCT01115231 is a clinical study titled "Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration". Risk factors for Age-related Macular Degeneration (AMD) involves genetic variations in the alternative pathway of complement inhibitor factor H. The complement system is part of the innate and adaptive immune system. Smoking is the only environmental factor known to increase the risk of Age-related ...
What is the current status of trial NCT01115231?
This trial is currently completed. The enrollment target is 223 participants. The study started on 2010-10. Estimated completion is 2016-12-31.
What conditions does trial NCT01115231 study?
This clinical trial studies the following conditions: Macular Degeneration.
Who is sponsoring clinical trial NCT01115231?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01115231 being conducted?
This trial has 2 study locations across South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
-
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
RECRUITING
-
Factors in Learning And Plasticity: Healthy Vision
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.